Cargando…

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study

The role of thoracic stereotactic body radiation therapy (SBRT) in addition to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant polymetastatic non-small-cell lung cancer (NSCLC) has not been well established. This retrospective study aimed to evaluate the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xia, Lu, Zhiqin, Zeng, Zhimin, Cai, Jing, Xu, Peng, Liu, Anwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448028/ https://www.ncbi.nlm.nih.gov/pubmed/34664886 http://dx.doi.org/10.1097/MD.0000000000027279

Ejemplares similares

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly
por: Wang, Peng, et al.
Publicado: (2016)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report
por: Wang, Xia, et al.
Publicado: (2021)

Characteristics and outcomes of primary pleural angiosarcoma: A retrospective study of 43 published cases
por: Wang, Xia, et al.
Publicado: (2022)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report
por: Liu, Ning, et al.
Publicado: (2021)

Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study
por: OuYang, Pu-Yun, et al.
Publicado: (2016)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis
por: Zhang, Haili, et al.
Publicado: (2021)

Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
por: Kuo, Hsing-Tao, et al.
Publicado: (2017)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer
por: Ge, Li, et al.
Publicado: (2017)

Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas
por: Fetcko, Kaleigh, et al.
Publicado: (2017)

The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma: A propensity score-matched analysis
por: Li, Tingting, et al.
Publicado: (2019)

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study
por: Tseng, Li-Chuan, et al.
Publicado: (2020)

Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis
por: Kuo, Yao-Hung, et al.
Publicado: (2019)

Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis
por: Que, Jenny, et al.
Publicado: (2020)

Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma
por: Carretero-González, Alberto, et al.
Publicado: (2019)

Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy
por: Que, Jenny, et al.
Publicado: (2020)

Simultaneous treatment of two lung cancer lesions with stereotactic MR-guided adaptive radiation therapy: A case report
por: Chen, Frank, et al.
Publicado: (2023)

SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review
por: Payne, Heather A., et al.
Publicado: (2021)

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2020)

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma
por: Oh, Dongryul, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity: A 5-year Follow-Up of an Investigational Study
por: Lee, Sea-Won, et al.
Publicado: (2014)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report
por: Dong, Min, et al.
Publicado: (2016)

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression
por: Roberto, Michela, et al.
Publicado: (2017)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
por: Xu, Li-Ming, et al.
Publicado: (2017)

Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies: Real-world evidence from a retrospective study using propensity score matching
por: Zhong, Liting, et al.
Publicado: (2021)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
por: Fangzheng, Wang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_203g1ev8e62upr11s62c69n57r